This market research report provides an overview of the current biologic sterile injectable market dynamics as well as what our survey respondents — all outsourcing decision makers — predict the market will look like in 2022. Key statistics include development-stage and marketed product volume, the proportion outsourced, and the number of CMOs required to complete the work. You can purchase the report or download a free preview by clicking here.
By Anna Rose Welch, editor, Biosimilar Development
An advocate from the Crohn's and Colitis Foundation shares details about the Foundation’s ongoing initiatives in terms of educating physicians, as well as what can be done to better understand and improve physicians’ biologics and biosimilar prescribing practices.
On March 5, 2019, Representative Anna Eshoo (D-CA) introduced H.R. 1520, the “Purple Book Continuity Act of 2019.” Recognizing that the Purple Book provides useful information to sponsors of biosimilar products — and that additional information may be even more useful — this bill would create new requirements for the FDA.
Network with and discuss the future of biosimilars with leaders from both innovator and biosimilar companies at the industry’s leading event directed to the legal, regulatory, and commercial aspects of the biosimilars marketplace. Be in the room as solutions are formulated to the complex regulatory and patent challenges ahead. Use our exclusive discount code for 10% off: P10-999-BIO19.